Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10205063 | PMC |
| http://dx.doi.org/10.1097/TP.0000000000004588 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.
Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.
Analysis of COVID-19 patient outcomes with molnupiravir treatment and the role of risk factors: a single-centre retrospective descriptive study.
Cent Eur J Public Health
December 2024
Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Kosice, Slovak Republic.
Objective: This study aims to describe the outcomes of COVID-19 patients treated with molnupiravir and to explore the associations with various risk factors.
Methods: We conducted a single-centre, descriptive, retrospective study without a comparison group.
Results: Out of 141 patients, 70 (49.
Successful Sequential Treatment From Remdesivir to Molnupiravir for Prolonged COVID-19 in a Patient With Follicular Lymphoma and Renal Pelvic Carcinoma: A Case Report.
Cureus
December 2024
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, JPN.
A 69-year-old Japanese male with follicular lymphoma and renal pelvic carcinoma presented with fever and cough, testing positive for SARS-CoV-2 via PCR. Chest CT revealed ground-glass opacities. Initially, his symptoms improved with a 10-day course of remdesivir (RDV), but they recurred.
View Article and Find Full Text PDFEfficacy and safety of antiviral therapies for the treatment of persistent COVID-19 in immunocompromised patients since the Omicron surge: a systematic review.
J Antimicrob Chemother
January 2025
Division of Infectious Diseases, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, University of Cologne, Kerpener Str. 62, 50939 Cologne, Germany.
Background: Persistent COVID-19 (pCOVID-19) in immunocompromised patients is characterized by unspecific symptoms and pulmonary infiltrates due to ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) replication. Treatment options remain unclear, leading to different approaches, including combination therapy and extended durations. The purpose of this study was to assess the efficacy and safety of antiviral therapies for pCOVID-19 in immunocompromised patients since the Omicron surge.
View Article and Find Full Text PDFComparative Effectiveness of Outpatient COVID-19 Therapies in Solid Organ Transplant Recipients.
Transpl Infect Dis
January 2025
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background: Multiple outpatient therapies have been developed for COVID-19 in high-risk individuals, but solid organ transplant (SOT) recipients were not well represented in controlled clinical trials. To date, few comparative studies have evaluated outcomes between outpatient therapies in this population.
Methods: We performed a retrospective cohort study using de-identified administrative claims data from OptumLabs Data Warehouse.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!